Via Therapeutics, LLC

Funding and NIH signals

• NIH award NIH awarded $277K (SBIR Phase I 1R43EY038569-01, new, notice Sep 18, 2026); 5 NIH awards totaling $2.54M in the last 12 months. NIH RePORTER 1R43EY038569-01 (Sep 18, 2026)
  Evidence (5 events)

  • Sep 18, 2026 · NIH RePORTER 1R43EY038569-01
    Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 1R43EY038569-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 277143; Administering IC: National Eye Institute; Project title: Novel Ocular Aerosol Drug Delivery Device for the Treatment Optimization of Glaucoma.; Organization type: Domestic For-Profits
  • Sep 17, 2026 · NIH RePORTER 2R44CA257783-02A1
    Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 2R44CA257783-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 660779; Administering IC: National Cancer Institute; Project title: Development of dermal targeting formulations for squamous cell carcinoma; Organization type: Domestic For-Profits
  • Sep 9, 2026 · NIH RePORTER 1R43AI197715-01
    Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 1R43AI197715-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 313674; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of Macrophage Targeting Inhaled Tigecycline Dry Powder Formulation for Treating Non-Tuberculous Mycobacterial (NTM) Infections; Organization type: Domestic For-Profits
  • Aug 28, 2026 · NIH RePORTER 1R41HL186958-01
    Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 1R41HL186958-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 315082; Administering IC: National Heart Lung and Blood Institute; Project title: Dry powders of whole blood prepared by thin-film freeze-drying; Organization type: Domestic For-Profits
  • Jul 10, 2026 · NIH RePORTER 5R44AI174337-03
    Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 5R44AI174337-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 971316; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals